Boston Pharma Appoints Dr. Peter Ho as CMO

(the “Company”) today announced the appointment of Peter Ho, MD, PhD, as Chief Medical Officer. Dr. Ho joins Boston Pharmaceuticals from Epizyme, where as Chief Medical Officer he led the company’s clinical development, translational medicine and regulatory affairs functions. At Boston Pharmaceuticals, Dr. Ho will oversee the clinical development the Company’s diversified portfolio of candidates.

“Peter is a tremendous addition to the Boston Pharmaceuticals team as we continue to build and advance our portfolio of differentiated therapeutics,” said Robert Armstrong, PhD, Chief Executive Officer and Co-Founder of Boston Pharmaceuticals. “Peter brings extensive expertise in translational medicine and clinical development and has overseen the progression of product candidates from early stage research through clinical development across multiple disease areas. We welcome him to our leadership team, and look forward to his contributions as we continue to advance candidates that we believe will ultimately improve patients’ lives.”

“Boston Pharmaceuticals is an exciting opportunity to advance the development of truly innovative programs across a range of therapeutic areas,” said Dr. Ho. “We are entering 2018 with great momentum. Two programs are in ongoing clinical trials, one in patients with advanced nonhematologic malignancies and one in patients with systemic lupus erythematosus, and we look forward to rapidly advancing our growing portfolio of candidates which have the potential to provide meaningful clinical benefit for patients.”

Prior to joining Epizyme, Dr. Ho was Co-Founder and President of BeiGene Ltd. His previous pharmaceutical positions included Vice President of Oncology Clinical Development at Johnson and Johnson and Senior Vice President of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. Dr. Ho began his career in drug discovery and development at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, National Cancer Institute (NCI) followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals.

Over his career, Dr. Ho has been directly responsible for first-in-human dosing of 17 anticancer agents and has overseen the development of over 50 hematology and oncology compounds. His work has contributed to seven new chemical entity approvals to-date including Gleevec(r), Arranon(r), Tykerb(r), Promacta(r), Votrient(r), Tafinlar(r) and Mekinist(r) (all trademarks registered to Novartis). Dr. Ho completed his pediatrics residency at The Children’s Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. Food and Drug Administration (FDA) and the NCI. He received a BA in biology from The Johns Hopkins University, and MD and PhD degrees from Yale University. Dr. Ho serves on the Scientific Advisory Board of Accent Therapeutics and served as a member of the Pediatric Cancer Working Group of the Cancer Moonshot Task Force.